What type of study is this?

This is a In Vitro Study study (also classified as: Animal Study).

October 18, 2025BloodOpen Access

A CD22-Specific T-Cell Receptor Enables Effective Adoptive T-Cell Therapy for B-cell malignancies

View Full Paper

Ask AI

Bookmark

Authors

SRSimone RheinHelmholtz Association of German Research Centres NÇNeşe Çakmak-GörürMax Delbrück Center CGCorinna GrunertHelmholtz Association of German Research Centres

Discussion

Member takes

Implication

Preclinical analysis reveals that CD22 T-cell receptors improve efficacy in B-cell malignancies, suggesting a promising alternative to CD19 CAR-T therapy.

Key Points

CD22 T-cell receptor therapy shows superior effectiveness against B-cell malignancies compared to CD19 CAR-T cells, particularly in relapsed cases.
Using a humanized mouse model, the CD22 T-cell receptor demonstrated high efficacy against CD22low tumor cells from patients' samples.
In vivo validation confirmed that CD22 TCR-T cells effectively target cells expressing low levels of CD22, overcoming limitations seen with CD22 CAR-T therapy.
These findings indicate that CD22 TCR-based therapies could be a powerful alternative for patients with CD22low B-cell malignancies post-CD19 CAR-T treatment.

Cite This Study

Rhein et al. (2025) studied this question.

synapsesocial.com/papers/68f3b2fb3f213c1f8b4d34ab https://doi.org/10.1182/blood.2025029329

View Full Paper

Ask AI

Bookmark

Implication

Preclinical analysis reveals that CD22 T-cell receptors improve efficacy in B-cell malignancies, suggesting a promising alternative to CD19 CAR-T therapy.

A CD22-Specific T-Cell Receptor Enables Effective Adoptive T-Cell Therapy for B-cell malignancies

Discussion

Member takes

Implication

Key Points

Cite This Study

A CD22-Specific T-Cell Receptor Enables Effective Adoptive T-Cell Therapy for B-cell malignancies

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider